TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06672133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Given：IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adebrelimab
Description: Given：IV
Study: NCT06226818

Intervention type: OTHER
Intervention: completion of scales and questionnaires
Description: Patient questionnaires Abuse assessment Screen, Evaluation of the PCL-5 score, Measurement of insomnia severity indexes (ISI), quality of life scores (WHOQOL-BREF), anxiety and depression using the HAD scale (Hospital Anxiety and Depression), self-esteem score using the Rosenberg scale, feeling of security and well-being using five-point Likert scales.~Questionnaire on daily and occasional smoking, alcohol consumption using the Alcohol Use Disorders Identification Test-Concise (AUDIT-C), cannabis dependence using the Cannabis Abuse Screening Test (CAST) and use of other psychoactive substances.

Intervention type: OTHER
Intervention: completion of scales and questionnaires
Description: Patient questionnaires Abuse assessment Screen, Evaluation of the PCL-5 score, Measurement of insomnia severity indexes (ISI), quality of life scores (WHOQOL-BREF), anxiety and depression using the HAD scale (Hospital Anxiety and Depression), self-esteem score using the Rosenberg scale, feeling of security and well-being using five-point Likert scales.~Questionnaire on daily and occasional smoking, alcohol consumption using the Alcohol Use Disorders Identification Test-Concise (AUDIT-C), cannabis dependence using the Cannabis Abuse Screening Test (CAST) and use of other psychoactive substances.
Study: NCT05641155

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Multipolar Stimulation (FMS) strategy
Description: Adult cochlear implant recipients receiving different combinations of alternative modes and, sound coding parameters.
Study: NCT05113394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM sublingual Immunotherapy
Description: HDM-SLIT tablet (Odactra®/Acarizax®) is a rapidly dissolving, freeze-dried, oral lyophilizate for oromucosal treatment, which contains a 1:1 mixture of two allergen extracts derived for the cultivated house dust mites, D. pteronyssinus and D. farinae. These species are included in SLIT tablet and subcutaneous immunotherapy administered for the treatment of allergic rhinitis and asthma in the pediatric and adult populations. The tablet dissolves within seconds after contact with a wet surface such as the oral mucosa. Participants will be administered the drug sublingually for 3 years.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sublingual therapy
Study: NCT05629585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dato-DXd
Description: Experimental drug. Provided in 100mg vials. IV infusion
Study: NCT04794699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE397
Description: IDE397 dosed orally
Study: NCT05629585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dato-DXd
Description: Experimental drug. Provided in 100mg vials. IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Experimental drug. Provided in 50mg vials. IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Active Comparator. Tablet. Oral route of administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Active Comparator. Provided in 100mg vials. IV infusion
Study: NCT06384261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cusatuzumab
Description: CD70 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: BCL-2 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: BCL-2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Hypomethylating agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Hypomethylating agent
Study: NCT04791709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Happy Older Latinos are Active (HOLA)
Description: HOLA is a multicomponent health promotion intervention. First component is a one-on-one social and physical activation with the participant and the community health worker (CHW). Each session will last approximately 30 minutes at day 1 and week 8. The second component is a group walk led by a CHW for 45 minutes, 3 times a week, for 16 weeks. The third component consists of scheduling pleasant events at the end of each group walk session.
Study: NCT06672133

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT06671210

Intervention type: DEVICE
Intervention: Urine and vaginal swab self-control
Description: Each participant provided urine and vaginal swabs for HPV testing.
Study: NCT05778266

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-citrulline
Description: oral supplementation of pure L-citrulline (6 g) for twelve weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-citrulline
Description: oral supplementation of pure L-citrulline (6 g) for twelve weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carboxymethyl cellulose
Description: oral supplementation of Carboxymethyl cellulose (6 g) as a placebo, for twelve weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Intervals Training
Description: participants will have sessions 3 days a week for twelve weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High Intensity Intervals Training
Description: participants will have sessions 3 days a week for twelve weeks
Study: NCT04418440

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Souvenaid oral nutritional supplement (Nutricia)
Description: Daily dose of a commercially available oral nutritional supplement based around the active compound recipe Fortasyn Connect, produced by Nutricia, Danone.
Study: NCT04982588

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic CoreValve™ Evolut™ PRO System
Description: The system comprised of the following three components:~1. CoreValve™ Evolut™ PRO Transcatheter Aortic Valve (TAV)~2. EnVeo™ PRO Delivery Catheter System (DCS)~3. EnVeo™ PRO Loading System (LS)
Study: NCT06536439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-operative explanation of the procedure (DIPLANN + CT)
Description: Pre-operative study visit explaining the RAPN procedure using the 3D model / DIPLANN-tool (with or without classical CT imaging). Included in this visit is a pre-operative physical examination (height, weight, abdominal examination), pre-operative blood examination (Hb, creatinin, eGFR) and patient questionnaires regarding patient knowledge, patient anxiety and patient quality of life.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-operative surgical planning (DIPLANN + CT)
Description: Online assessment by surgeon regarding clamping strategy. Assisted by DIPLANN-tool + CT scan.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RAPN (DIPLANN + CT)
Description: Robot-assisted partial nephrectomy surgical procedure. Peri-operative guidance by DIPLANN-tool + CT scan.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-operative explanation of the procedure (CT only)
Description: Pre-operative study visit explaining the RAPN procedure using CT imaging alone. Included in this visit is a pre-operative physical examination (height, weight, abdominal examination), pre-operative blood examination (Hb, creatinin, eGFR) and patient questionnaires regarding patient knowledge, patient anxiety and patient quality of life.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-operative surgical planning (CT only)
Description: Online assessment by surgeon regarding clamping strategy. Assisted by classical CT imaging only.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RAPN (CT only)
Description: Robot-assisted partial nephrectomy surgical procedure. Peri-operative guidance by CT imaging only.
Study: NCT05919108

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine Therapy
Description: Undergo endocrine therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy
Description: Undergo endocrine therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy of breast
Description: Undergo breast biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of breast
Description: Undergo breast biopsy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neratinib
Description: Taken by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Taken by mouth

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mammogram
Description: Undergo Mammogram

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mammogram
Description: Undergo Mammogram

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo breast Magnetic Resonance Imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo breast Magnetic Resonance Imaging

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breast Surgery
Description: Undergo Breast Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Surgery
Description: Undergo Breast Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Undergo Ultrasound
Study: NCT06003231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: disitamab vedotin
Description: Given into the vein (IV, intravenous) every 2 weeks
Study: NCT06563531

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological thromboprophylaxis and elastic compression
Description: Patients benefit from thromboembolism prevention through pharmacological thromboprophylaxis and elastic restraint after total hip or knee arthroplasty.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacological thromboprophylaxis without elastic compression
Description: Patients benefit from thromboembolism prevention through pharmacological thromboprophylaxis only after total hip or knee arthroplasty.
Study: NCT06566482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-esketamine combination
Description: Patient-controlled analgesia is established with dexmedetomidine (1 μg/ml), esketamine (1 mg/ml), and sufentanil (1 μg/ml) in a total volume of 100 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient-controlled analgesia is established with sufentanil (1 μg/ml) in a total volume of 100 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours after surgery.
Study: NCT06023550

Intervention type: OTHER
Intervention: Treatment with surgery and/or conservative measures
Description: Patients will be treated according to established clinical practice with surgery and/or conservative measures.

Intervention type: OTHER
Intervention: Treatment with surgery and/or conservative measures
Description: Patients will be treated according to established clinical practice with surgery and/or conservative measures.

Intervention type: OTHER
Intervention: Treatment with surgery and/or conservative measures
Description: Patients will be treated according to established clinical practice with surgery and/or conservative measures.

Intervention type: OTHER
Intervention: Treatment with surgery and/or conservative measures
Description: Patients will be treated according to established clinical practice with surgery and/or conservative measures.
Study: NCT06497491

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GNR-086
Description: GNR-086 is administered as a subcutaneous injection at a dose of 4 mg/kg once every 4 weeks for 24 weeks.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ilaris®
Description: Ilaris® is administered as a subcutaneous injection at a dose of 4 mg/kg once every 4 weeks for 24 weeks.
Study: NCT04656275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: BI 1323495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: BI 1323495
Study: NCT04794699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous infusion
Study: NCT04656275

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05601752

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous genetically modified ADP-A2M4CD8 cells
Description: Infusion of autologous genetically modified ADP-A2M4CD8 cells on Day 1

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab
Description: Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1 followed by nivolumab 480 mg IV at Week 4 and then every four weeks
Study: NCT06190509

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine
Description: The candidate pentavalent bioconjugate vaccine (Candi5V) is administered twice, 2 months apart, with adjuvant.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine
Description: The candidate pentavalent bioconjugate vaccine (Candi5V) is administered twice, 2 months apart, with adjuvant.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine
Description: The candidate pentavalent bioconjugate vaccine (Candi5V) is administered twice, 2 months apart without adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine
Description: The candidate pentavalent bioconjugate vaccine (Candi5V) is administered twice, 2 months apart without adjuvant

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vaccine
Description: The placebo is administered twice, 2 months apart
Study: NCT04383119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin in monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine, control arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention: Observational Cohort
Description: Treatment according clinical practice
Study: NCT05440149

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: No PMRT for mastectomy / No regional RT for BCS
Description: * Regional RT includes high-tangent field, and can include undissected axilla.~* The definition of high-tangent is that the upper margin of the radiotherapy field located within 2 cm of the humeral head to include axillary levels I and II.~* Both hypofractionated and conventionally fractionated radiation therapy are allowed, and 3-dimensional or intensity modulated radiotherapy are allowed. The electron beam can also be used.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PMRT for mastectomy / WBI + Regional RT for BCS
Description: * Regional RT includes high-tangent field, and can include undissected axilla.~* The definition of high-tangent is that the upper margin of the radiotherapy field located within 2 cm of the humeral head to include axillary levels I and II.~* Both hypofractionated and conventionally fractionated radiation therapy are allowed, and 3-dimensional or intensity modulated radiotherapy are allowed. The electron beam can also be used.
Study: NCT06418425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: counselling on home-based exercise program and dietary protein intake
Description: Participants in the intervention group will be on a home-based exercise program and go through counselling on dietary protein intake with the aim of achieving prevention of frailty status. Participants will be required to attend the 3 study visits throughout the study period. Research procedures include physical measurements (eg. Weight, height, waist and hip circumference, calf circumference, hand grip strength, blood pressure, short physical performance battery tests), administration of questionnaires on sociodemographics, physical activity, dietary habits, smoking, alcohol, health conditions, health-related quality of life, clinical frailty status and sarcopenia screening. At three months and twelve months, the intervention group participants will see the care coordinators who will check their compliance to the exercise programme and high protein diet, reinforce the interventions.
Study: NCT06497231

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beautifil II LS
Description: Beautifil II LS is a low shrinkage bioactive giomer resin composite.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nanohybrid resin composite material
Description: Nanohybrid resin composite is a type of restorative material that features nano-sized fillers as a main component.
Study: NCT05710107

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PENG + LFC Block
Description: Subjects assigned to this group will receive PENG + LFC Block

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: QL Block
Description: Subjects randomized to this group will receive a QL Block
Study: NCT06469398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutera Laser System
Description: Subjects will receive up to 6 laser treatments
Study: NCT06290232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetoscopic Laser Photocoagulation
Description: Pregnant patients diagnosed with type II vasa previa will undergo fetoscopic laser photocoagulation of the involved fetal vessels. FLP will be performed laparoscopically using a fetoscope (tiny telescope) and a laser device inside of the womb. This procedure will be completed at 30w0d to 32w6d gestational age.
Study: NCT06405074

Intervention type: DEVICE
Group type: OTHER
Intervention: low intensity focused ultrasound (LIFU)
Description: Low-intensity focused ultrasound (LIFU) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. LIFU is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth.~Much lower intensities of focused ultrasound (LIFU) are used so that tissue damage does not occur, but neural activity can be modulated. LIFU utilizes acoustic energy at much lower levels to affect tissue by mechanical effects.

Intervention type: DEVICE
Group type: OTHER
Intervention: low intensity focused ultrasound (LIFU)
Description: Low-intensity focused ultrasound (LIFU) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. LIFU is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth.~Much lower intensities of focused ultrasound (LIFU) are used so that tissue damage does not occur, but neural activity can be modulated. LIFU utilizes acoustic energy at much lower levels to affect tissue by mechanical effects.
Study: NCT04794699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Intravenous infusion
Study: NCT05744869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBAT Implementation
Description: Implementation of the SBAT Program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care for children with asthma
Study: NCT05913323

Intervention type: DEVICE
Intervention: Rapid Expiratory Occlusion Monitor (REOM)
Description: Device for which Health Canada approval (ITA Authorization) has been obtained for use in the present study.

Intervention type: DEVICE
Intervention: Rapid Expiratory Occlusion Monitor (REOM)
Description: Device for which Health Canada approval (ITA Authorization) has been obtained for use in the present study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard oscillometry
Description: tremoflo device-100, Thorasys Thoracic Medical Systems Inc., Montreal, Canada
Study: NCT05857345

Intervention type: OTHER
Intervention: Collection of breastmilk
Description: Collection of breastmilk and other information about the participant
Study: NCT05736796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumber strengthening exercises
Description: Complex Training program to Achieve the normal postural. Lumber Extension Excersie will be done to prevent the lumber straighten.

Intervention type: OTHER
Group type: OTHER
Intervention: General cervical Exercise
Description: Students of this group will perform general exercises of the cervical region to strengthen the Muscles.
Study: NCT05913323

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard oscillometry
Description: tremoflo device-100, Thorasys Thoracic Medical Systems Inc., Montreal, Canada

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard pulmonary function test
Description: Standard-of-care respiratory test.
Study: NCT06668220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine has become more popular as a caudal adjuvant in children; it is a highly selective α2 agonist with sedative and analgesic properties. Dexmedetomidine possesses anxiolytic, sedative, sympatholytic, and analgesic properties without respiratory depressant effects In addition; dexmedetomidine has the ability to reduce both the anesthetic and opioid analgesic requirements during the perioperative period.
Study: NCT05913323

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard pulmonary function test
Description: Standard-of-care respiratory test.